Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Multicenter Study
. 2014 Apr;39(8):834-42.
doi: 10.1111/apt.12670. Epub 2014 Feb 24.

Association Between High Dietary Intake of the n-3 Polyunsaturated Fatty Acid Docosahexaenoic Acid and Reduced Risk of Crohn's Disease

Free PMC article
Multicenter Study

Association Between High Dietary Intake of the n-3 Polyunsaturated Fatty Acid Docosahexaenoic Acid and Reduced Risk of Crohn's Disease

S S M Chan et al. Aliment Pharmacol Ther. .
Free PMC article


Background: There are plausible mechanisms for how dietary docosahexaenoic acid (DHA), an n-3 polyunsaturated fatty acid, could prevent Crohn's disease (CD).

Aim: To conduct a prospective study to investigate the association between increased intake of DHA and risk of CD.

Methods: Overall, 229 702 participants were recruited from nine European centres between 1991 and 1998. At recruitment, dietary intakes of DHA and fatty acids were measured using validated food frequency questionnaires. The cohort was monitored through to June 2004 to identify participants who developed incident CD. In a nested case-control analysis, each case was matched with four controls; odds ratios (ORs) were calculated for quintiles of DHA intake, adjusted for total energy intake, smoking, other dietary fatty acids, dietary vitamin D and body mass index.

Results: Seventy-three participants developed incident CD. All higher quintiles of DHA intake were inversely associated with development of CD; the highest quintile had the greatest effect size (OR = 0.07; 95% CI = 0.02-0.81). The OR trend across quintiles of DHA was 0.54 (95% CI = 0.30-0.99, Ptrend = 0.04). Including BMI in the multivariate analysis, due to its correlation with dietary fat showed similar associations. There were no associations with the other dietary fatty acids studied.

Conclusion: There were inverse associations, with a biological gradient between increasing dietary docosahexaenoic acid intakes and incident Crohn's disease. Further studies in other populations should measure docosahexaenoic acid to determine if the association is consistent and the hypothesis tested in randomised controlled trials of purely docosahexaenoic acid supplementation.

Comment in

Similar articles

See all similar articles

Cited by 21 articles

See all "Cited by" articles


    1. Jostins L, Ripke S, Weersma RK, et al Host‐microbe interactions have shaped the genetic architecture of inflammatory bowel disease. Nature 2012; 491: 119–24 - PMC - PubMed
    1. Abraham C, Cho JH. Inflammatory bowel disease. N Engl J Med 2009; 361: 2066–78 - PMC - PubMed
    1. Ananthakrishnan AN. Environmental triggers for inflammatory bowel disease. Curr Gastroenterol Rep 2013; 15: 302. - PMC - PubMed
    1. Fritsche K. Fatty acids as modulators of the immune response. Annu Rev Nutr 2006; 26: 45–73 - PubMed
    1. Novak TE, Babcock TA, Jho DH, Helton WS, Espat NJ. NF‐kappa B inhibition by omega ‐3 fatty acids modulates LPS‐stimulated macrophage TNF‐alpha transcription. Am J Physiol Lung Cell Mol Physiol 2003; 284: L84–9 - PubMed

Publication types